Results 121 to 130 of about 1,481 (180)

Nursing Staff Training on Compounded Intranasal Ketamine for Treatment-Resistant Depression [PDF]

A large proportion of individuals with major depressive disorder (MDD) do not receive adequate therapy benefits from conventional monoaminergic antidepressant drugs, leading to treatment-resistant depression (TRD) (Di Vincenzo et al., 2021). Treating MDD
Lal, Rimisha, Son, Gabrielle
core   +1 more source

Social determinants and distance from certified treatment centers are associated with initiation of esketamine nasal spray among patients with challenging-to-treat major depressive disorder. [PDF]

Medicine (Baltimore), 2023
Liberman J, Pesa J, Rui P, Joshi K, Harding L.   +4 more
europepmc   +1 more source

Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior. [PDF]

J Clin Psychopharmacol, 2021
Canuso CM, Ionescu DF, Li X, Qiu X, Lane R, Turkoz I, Nash AI, Lopena TJ, Fu DJ.   +8 more
europepmc   +1 more source

Assessing the meaningful change threshold of Quality of Life in Depression Scale using data from two phase 3 studies of esketamine nasal spray. [PDF]

J Patient Rep Outcomes, 2022
Rozjabek H, Li N, Hartmann H, Fu DJ, Canuso C, Jamieson C.   +5 more
europepmc   +1 more source

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials. [PDF]

Arch Womens Ment Health, 2022
Jones RR, Freeman MP, Kornstein SG, Cooper K, Daly EJ, Canuso CM, Nicholson S.   +6 more
europepmc   +1 more source

Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies. [PDF]

Medicine (Baltimore)
Ouyang Y, Li J.
europepmc   +1 more source

Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States. [PDF]

J Manag Care Spec Pharm
Clemens K, Zhdanava M, Teeple A, Voegel A, Joshi K, Shah A, Chen C, Pilon D.   +7 more
europepmc   +1 more source

Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies. [PDF]

Int J Neuropsychopharmacol
Morrison RL, Singh J, Daly E, Fedgchin M, Ochs-Ross R, Karcher K, Lane R, Cooper K, Sanacora G, Maruff P, Drevets WC.   +10 more
europepmc   +1 more source

Use of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression in Routine Practice: A Real-World French Study. [PDF]

Depress Anxiety
Samalin L, Mekaoui L, Rothärmel M, Sauvaget A, Wicart C, Dupin J, Cohignac V, Gaudre-Wattinne E.   +7 more
europepmc   +1 more source